Liquidia Corporation to Participate in Upcoming Investor Conferences
Liquidia (NASDAQ: LQDA) will participate in two investor conferences in May 2026 with senior management presenting company updates.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia (NASDAQ: LQDA) will participate in two investor conferences in May 2026 with senior management presenting company updates.
Executives Michael Kaseta and Jason Adair will hold fireside chats and one-on-one meetings at BofA Securities Health Care Conference (May 13, 8:40 am PT, Las Vegas) and H.C. Wainwright Bioconnect at NASDAQ (May 19, 9:30 am ET, New York). Webcast access and replays are on the Investors page for at least 30 days.
Details
News Market Reaction – LQDA
On May 6, the day this news came out, LQDA closed 5.01% above the previous close.
Data tracked by StockTitan Argus for the May 6 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced it will participate in upcoming investor conferences.
BofA Securities 2026 Health Care Conference
Date: Wednesday, May 13, 2026 at 8:40 am PT
Location: Las Vegas, Nevada
In addition to hosting one-on-one meetings, Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company’s business during a fireside chat beginning at 8:40 am Pacific Time.
H.C. Wainwright 4th Annual Bioconnect Investor Conference at NASDAQ
Date: Tuesday, May 19, 2026, 9:30 a.m.
Location: New York, NY
In addition to hosting one-on-one meetings, Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company's business during a fireside chat session beginning at 9:30 am Eastern Time.
Access to these events will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A replay of the webcast will be archived on the Company's website for at least 30 days.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® Technology. PRINT enabled the development of YUTREPIA® (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
Jason.adair@liquidia.com
Media:
media@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.